EndoQuest Robotics is collaborating with NVIDIA to integrate protocols within its endoluminal robotic surgery technology as it progresses towards commercialisation.
The company’s pair-up will focus on integrating the visualisation system, robotic control, and secure cloud services of its Endoluminal Surgical (ELS) system by using Nvidia’s computing and software stack programmes, including Nvidia Holoscan and Nvidia AI Enterprise.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
EndoQuest’s robot is designed for performing gastrointestinal (GI) procedures through natural orifices or a single transumbilical incision. Surgical robots such as EndoQuests’ help reduce external scars and patient trauma.
The US-based company said the aim of the Nvidia integration would be to deliver real-time image processing, robotic control and cloud-enabled intelligence within a unified architecture.
EndoQuest’s CEO Eduardo Fonseca explained: “By powering our visualisation, control and secure cloud services with Nvidia’s industry-leading technology, we aim to streamline our system architecture for performance, reliability and clinical scalability.
“This unified architecture is critical to advancing our technology for endoluminal robotic surgery and reaching commercialisation.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataTechnology from Nvidia will also be applied for low-latency sensor processing and 3D visualisation, precise and time-synchronised motion control, and secure cloud connectivity. EndoQuest said these capabilities will support fleet management, data services and AI deployment, with findings from the work anticipated to guide the company’s product development and commercialisation strategy for its future robotic systems.
EndoQuest’s ELS is currently under evaluation in the company’s PARADIGM trial (NCT06133387). The study was initiated in May 2025 following EndoQuest’s receipt of an investigational device exemption (IDE) from the US Food and Drug Administration (FDA) in December 2024. PARADIGM is evaluating the safety and performance of the ELS’s use in subjects undergoing specified transanal endoluminal procedures in the rectum and sigmoid colon, with the multi-centre study due for completion in early 2026.
Pre-clinical evidence for ELS suggests robot-assisted endoscopic submucosal dissection (ESD) proved more effective and safer than conventional ESD for colonic lesions, with robot-assisted ESD attributable to a higher rate of complete en bloc resection, shorter procedure times, and fewer muscle injuries and perforations compared to the conventional method.
The overall global robotic surgical systems market is growing at a compound annual growth rate (CAGR) of 12.1% and is projected to reach a valuation of $9.2bn by 2034, up from $2.9bn in 2024, according to a GlobalData market model.
First launched in 2000, Intuitive Surgical’s da Vinci surgical robot dominates the robotic surgery sector, with a US and global market share of 86.5% and 76%, respectively.
However, other entrants such as EndoQuest are trying to gain a market foothold with specific procedural focuses. Most recently, Microbot’s LIBERTY, a single-use, remotely operated robotic system for peripheral endovascular procedures gained clearance from the FDA.
